Expand OCGN Menu
OCGN MENU

OCGN Latest Press Releases

-- November 8, 2024 --

Ocugen Provides Business Update with Third Quarter 2024 Financial Results Globe Newswire 6:45 AM

-- November 7, 2024 --

Ocugen Secures $30 Million in Debt Funding Globe Newswire 6:30 AM

-- October 28, 2024 --

Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024 Globe Newswire 6:30 AM

-- October 22, 2024 --

Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease Globe Newswire 7:02 AM

-- October 17, 2024 --

Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results Globe Newswire 7:30 AM

-- October 10, 2024 --

Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit Globe Newswire 7:00 AM

-- October 9, 2024 --

Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial Globe Newswire 6:30 AM

-- October 2, 2024 --

Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa Globe Newswire 6:30 AM

-- September 24, 2024 --

Ocugen to Participate in a Fireside Chat at Chardan's 8th Annual Genetic Medicines Conference Globe Newswire 7:30 AM

-- September 17, 2024 --

Kaskela Law LLC Announces Shareholder Investigation of Ocugen, Inc. (NASDAQ: OCGN) and Encourages Investors to Contact the Firm Business Wire 8:00 AM

-- September 9, 2024 --

Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop Globe Newswire 6:30 AM

-- September 5, 2024 --

Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit Globe Newswire 7:00 AM

-- September 3, 2024 --

Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference Globe Newswire 7:30 AM

-- August 28, 2024 --

Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST-A Modifier Gene Therapy Globe Newswire 6:30 AM

-- August 26, 2024 --

Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication Globe Newswire 7:02 AM

-- August 20, 2024 --

Ocugen, Inc. Investor Alert (NASDAQ: OCGN): Schubert Jonckheer & Kolbe LLP Investigating Potential Claims Against the Company's Officers and Directors Following Earnings Restatement and Possible Insider Trading PRNewswire 9:00 AM

-- August 8, 2024 --

Ocugen Provides Business Update with Second Quarter 2024 Financial Results Globe Newswire 6:45 AM

-- August 5, 2024 --

Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa Globe Newswire 6:30 AM

-- August 2, 2024 --

Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock Globe Newswire 3:22 PM

-- July 31, 2024 --

Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock Globe Newswire 9:15 PM
Ocugen, Inc. Announces Proposed Public Offering of Common Stock Globe Newswire 4:15 PM

-- July 29, 2024 --

Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results Globe Newswire 7:02 AM

-- July 25, 2024 --

Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410-A Novel Modifier Gene Therapy Globe Newswire 6:30 AM

-- June 21, 2024 --

Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease Globe Newswire 7:00 AM

-- June 20, 2024 --

Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400-First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication Globe Newswire 6:30 AM

-- June 10, 2024 --

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen Newsfile 12:17 PM
DEADLINE ALERT for SOND, OCGN, VFS, and QDEL: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders Globe Newswire 12:07 PM
OCGN DEADLINE TODAY: TOP RANKED ROSEN LAW FIRM Encourages Ocugen, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important June 10 Deadline in Securities Class Action First Filed by the Firm OCGN Globe Newswire 11:46 AM
OCGN DEADLINE TODAY: ROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important June 10 Deadline in Securities Class Action First Filed by the Firm OCGN Business Wire 10:41 AM
DEADLINE TODAY: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm Business Wire 10:20 AM

-- June 9, 2024 --

OCGN FINAL DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important June 10 Deadline in Securities Class Action First Filed by the Firm - OCGN Newsfile 9:17 PM
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen Newsfile 8:14 AM

-- June 8, 2024 --

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 10 Deadline in Securities Class Action First Filed by the Firm - OCGN Newsfile 9:16 PM